• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Aluda Pharmaceuticals

Wednesday, June 05, 2024
Start-Up Stadium Session
Immunology
Company Description: Aluda was founded to reexamine how fundamental cell processes are altered by disease, combining rational drug design with holistic objectives to make wider impact. We discovered that Vimentin, a filament protein with well-validated roles in disease, is druggable, creating a new kind of disease-modifying action that blocks how many cell processes that are normally protective and regenerative shift to over-stimulated and maladapted in disease. Lead small molecule ALD-R491 is ready for Phase I. Expert KOL and regulatory guidance outlines a viable plan to NDA filing in 36 months in sepsis, followed by expansion in Severe Crohn’s with fibrotic strictures.

Aluda Pharmaceuticals
Company Website: http://www.aludapharm.com

Company HQ City

Menlo Park

Company HQ State

ca

Company HQ Country

United States

CEO/Top Company Official

Ruihuan Chen
Primary Speaker
Deebie Symmes, MBA
CBO/COO
Aluda Pharmaceuticals
Back to Session List

white squarewhite

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS